KDR and neoplasm: Although currently, a monoclonal anti-VEGFR2 antibody is on the market, studies on antibodies have focused on reducing the size of these peptides to address the problem of bioavailability and limited tumor distribution, which eventually led to the discovery of a new type of antibody in camels that is naturally light-chain; they do not have their first constant domain (CH1) in the heavy chain (16).